HYPD
Hyperion DeFi·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About HYPD
Hyperion Defi, Inc.
A clinical stage biopharmaceutical company
23461 South Pointe Drive, Suite 390, Laguna Hills, CA 92653
--
Hyperion DeFi, Inc., formerly known as PGP Holdings V, Inc., was incorporated under the laws of Florida on March 12, 2014 and re-incorporated in Delaware as Eyenovia, Inc., a clinical-stage biopharmaceutical company that has developed a range of ophthalmic products using its patented piezoelectric printing technology to provide microtherapy for ocular skin. This microdosing technology has the potential to replace traditional high-dose applications (such as the delivery of conventional eye drops of 30-50μL), which are often overdosed or underdosed when used for topical application of ophthalmic therapeutic agents. They believe that their micro-therapeutic product candidates may be able to achieve pharmacological effects similar to traditional high-dose applications while reducing the adverse effects associated with these technologies.
Company Financials
EPS
HYPD has released its 2025 Q3 earnings. EPS was reported at 0.05, versus the expected -7.2, beating expectations. The chart below visualizes how HYPD has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
HYPD has released its 2025 Q3 earnings report, with revenue of 302.51K, reflecting a YoY change of 18515.75%, and net profit of 6.63M, showing a YoY change of 184.00%. The Sankey diagram below clearly presents HYPD's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
